What do systematic reviews say?

Pazopanib plus lapatinib vs lapatinib

Pazopanib plus lapatinib may leads to higher overall survival compared with lapatinib (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 2.71 [1.16, 6.31]
  1 study · 117 participants
  Low